On May 25, 2023, Nascent Biotech, Inc. and BioRay Pharmaceutical Co mutually terminated the license agreement entered into on March 31, 2021. Under the terms of the termination agreement the Company now has regained worldwide rights granted under the license agreement at no cost to either Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0948 USD | +5.33% | -5.01% | -45.17% |
1st Jan change | Capi. | |
---|---|---|
-45.17% | 15.35M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement